Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2011-10-11 Capital/Financing Update
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Shortfall Announcement 2 pages 177.9KB
Capital/Financing Update Classification · 95% confidence The document is titled 'SHORTFALL ANNOUNCEMENT' and discusses the results of a rights issue, including the amount raised, the number of shares issued, and the underwriting agreement. It provides details about the capital raising activity but does not contain financial statements or detailed financial analysis. The document length is 4335 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full financial report, earnings release, or regulatory filing beyond the capital raising update. Therefore, this document fits best under the category of Capital/Financing Update (CAP).
2011-10-11 English
Notice of Meeting and Proxy Form 10 pages 867.7KB
Board/Management Information Classification · 95% confidence The document is a Notice of General Meeting for CBio Limited, detailing the convening of a shareholder meeting to consider resolutions related to the removal and appointment of directors. It includes the date, location, agenda items (resolutions), explanatory memorandum, voting instructions, and proxy form information. The content focuses on governance matters, specifically board composition changes, and is not a report of voting results or a proxy solicitation document. It is not an annual report, earnings release, or any financial report. The document is a formal notice to shareholders about the meeting and the proposed resolutions to be voted on, which fits the category of Board/Management Information (MANG) as it announces changes and proposed changes in the company's board of directors.
2011-09-25 English
Annual Report to shareholders 79 pages 522.1KB
Annual Report Classification · 100% confidence The document is titled 'FINANCIAL REPORT FOR THE YEAR ENDED 30 JUNE 2011' and contains detailed sections typical of an annual report, including chairman's address, CEO review, corporate governance statement, directors' report, comprehensive financial statements (income statement, balance sheet, cash flows), notes to financial statements, directors' declaration, auditor's independence declaration, and independent audit report. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes detailed company and market information, clinical trial results, strategic direction, and financial data, all consistent with a comprehensive annual report. Therefore, this document fits the definition of an Annual Report (10-K). FY 2011
2011-09-20 English
Updated Investor Presentation 35 pages 680.2KB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation Post-Interim Results Update' and contains detailed information about clinical trial results, development plans, market summaries, capital structure, and commercial agreements related to a pharmaceutical product. It includes extensive data and analysis typical of an investor presentation, such as trial design, efficacy signals, market potential, and funding use. There is no indication that this is a regulatory filing, earnings release, or annual/interim report. The document is comprehensive and clearly intended as a presentation to investors about the company's progress and strategy. Therefore, the document fits the category of an Investor Presentation (IP).
2011-09-18 English
249D Notice Update 2 pages 194.7KB
Board/Management Information Classification · 95% confidence The document is a statement from CBio Limited regarding a requisitioned general meeting requested by certain shareholders to remove and appoint directors. It discusses the requisition notice, the shareholders involved, the proposed resolutions, and the company's compliance with legislative requirements to convene the meeting. There is no financial data, earnings information, or detailed report content. The document is an announcement about a shareholder meeting and related board changes, not the meeting materials themselves or voting results. This fits best under Board/Management Information (MANG) as it concerns changes in the company's board of directors and related shareholder actions.
2011-09-11 English
Announcement of Underwritten Rights Issue 3 pages 193.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 5 September 2011 from CBio Limited regarding an underwritten non-renounceable rights issue to raise capital. It details the offer terms, use of proceeds, important dates, and background on the company and its drug candidate XToll. The content focuses on fundraising activities and capital structure changes, specifically a rights issue underwritten by Zheng He Securities. There are no financial statements or detailed financial performance data presented, nor is this a report or transcript. The document is a capital/financing update announcing a rights issue and related financing details. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6257 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2011-09-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.